Kalios
← Stacks

Stack — Skin & hair

GLOW Stack — GHK-Cu + BPC-157 + TB-500 · Tested together in people: none published

Gray market

Checked · 17 sources · 5 corrections on this page · No vendors · No affiliates · No one buys a word of it

GHK-Cu: no FDA ruling on the injectable — not on any list

Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.

Injectable GHK-Cu: not legal to compound Non-injectable GHK-Cu is on FDA’s 503A Category 1 list, and FDA plans a committee review of it before the end of February 2027. The injectable nomination was withdrawn. See every change →

Built on: Skin, Hair & Connective Tissue

The receipt

0 studies gave them to people together

Evidence on the combination
No data

None published

No study that gave them to people together is among the sources Kalios cites. Reports of people already taking both, registered trials, conference talks, patents and makers’ own tests don’t count.

What each does alone

Mechanism overlap · reasoning, not evidence

BPC-157
Peptide — Tissue Repair & Cytoprotection
GHK-Cu
Peptide — Copper Tripeptide, Skin & Connective Tissue
TB-500
Peptide Fragment — Tissue Repair (Thymosin β4 17–23)

Reasoning, not evidence: what each is described to do says nothing about what they do together.

References

No clinical trial has studied the GHK-Cu + BPC-157 + TB-500 combination in humans. References below cover the individual components and the mechanistic framework.

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. (Comprehensive GHK-Cu review.)
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730.
  3. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264.
  4. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353.
  5. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17703734.
  6. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
  7. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
  8. Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887.
  9. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133.
  10. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. PMID: 15565145.
  11. Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037013.
  12. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID: 15655171.
  13. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20721598.
  14. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864.
  15. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B. FDA.gov, updated 2025-2026.
  16. WADA Prohibited List 2026. Sections S0 and S2. World Anti-Doping Agency.
  17. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)

→ Calculator — vial-to-syringe math

See every change to this page → · Status now →

Checked 13 Oct 2026